L8, Repeat Expansion Disorders Flashcards
1
Q
Definition and rough basis of genetic anticipation:
A
- Earlier onset, increasing severity in later generations (e.g. myotonic dystrophy)
- Increased numbers of individuals with symptoms in later generations (e.g. Fragile X syndrome)
- Based upon expanded numbers of unstable microsatellite repeats (Short tandem repeat of up to 9nts)
2
Q
Define dynamic mutation:
A
- Unstable repeats that can expand on parental transmission and in somatic tissue
- Basis for genetic anticipation
3
Q
Key examples of repeat expansion disorders with implicated gene region:
A
- Huntington’s disease (coding exon)
- Fragile X; FRAXA or FXTAS (5’UTR)
- SBMA/Spinal and Bulbar Muscular Atrophy (coding exon)
- DM/ Myotonic dystrophy (Type 1: 3’UTR)
4
Q
How many human REDs are there currently:
A
- Over 50, with 13 different sequence repeats associated
5
Q
Characteristics of repeat expansion disorders:
A
- Generally, number of repeats positively correlates with disease severity, negatively correlates with age of onset
- Expansion of one disease causing repeat does not interfere with other repeat in patient’s genome
- Can be AD, AR or X-linked
6
Q
Mechanisms for REDs (x4):
A
- Expansion of non-coding repeats leading to LOF of gene containing repeat -> AR
- Expansion of CAG coding repeats leading to GOF and production of abnormal protein containing and expanded polyglutamine tract -> AD
- Expansions resulting in GOF of RNA containing an expanded repeat -> AD
- Expansions resulting in repeat associated, non-ATG (RAN) translation of repeat containing RNA leading to production of toxic peptides -> AD
7
Q
Fragile X characeristics:
A
- Commonest cause of inherited intellectual disability
- Increased severity in males, relatively mild in females (random X-inactivation)
- Prevalence of FXS: 1 in 4000 to 1 in 7000
- Autism common
- Mild abnormal facial features (sunken eyes, arched palate, large ears, macroorchidism)
- Otitis media, seizures, mitral valve prolapse, GI problems
8
Q
FRAXA site:
A
- Xq27.3
- First fragile site described on X chromosome
- CGG repeat expansion in 5’ UTR of FMR1 gene on X chromosome
9
Q
Thresholds for FXS:
A
- Stable: 6-44 repeats
- IM: 44-54 repeats
- Premutation: 55-200 repeats (associated with FXTAS, FXPOI)
- Full FRAX mutation: 200 to >4000 repeats
10
Q
Epigenetic mechanism of FMR1: (transcription under normal conditions vs FXS)
A
- if <40 CGG i.e. normal: FMRP produced in hESCs and differentiated cells (active euchromatin; DNA unmethylated) -> transcribed
- if >200 CGG, hESCs FMR1 transcribed and translated -> expanded FMR1 mRNA initiates silencing (>200 CGG, repressive heterochromatin, MeCpG and H3K9Me2 -> No FMRP expression (the transcript interacts back with the DNA to silence/methylate it)
11
Q
Role of FMRP:
A
- 71 kDa protein
- Normally localises to postsynaptic spaces of dendritic spines
- Shuttles in and out of the nucleus transporting target mRNAs
- Phosphorylated FMRP binds to and represses translation of ~400 target dendritic mRNAs (normal conditions)
- On receipt of synaptic signals, FMRP is de-phosphorylated. It no longer represses translation and allows synthesis of key synaptic plasticity proteins
- See FC
12
Q
Huntington’s disease: Characteristics
A
- Characterised by neuronal degeneration (most common monogenic cause)
- Clinical features include progressive, selective neural cell death associated with choreic (writhing, dance-like) movements and dementia
13
Q
What repeat sequence causes HD? Gene affected? Threshold repeats for disease:
A
- Expansion of CAG tri-nt repeat encoding glutamine (Q) in exon 1
- Affects HTT gene (4p16.3)
- Normal allele: 11-26 CAG repeats
- Mutable normal allele: 27-35 CAG repeats
- HD allele (reduced penetrance): 36-39
- HD allele: 39 to ~250 CAG repeats
- Paternal expression bias >7 CAG
14
Q
How can HD repeat numbers be estimated?
A
- PCR assay
- PCR primers flank repeat containing region -> size of PCR product is dependent on number of CAG repeats
15
Q
Htt structure; wild type protein
A
- Protein mainly consists of HEAT repeats (Huntingtin Elongation factor 3; subunit of protein phosphatase 2A and TOR1
- Widely expressed with highest levels in neurons of the CNS
- The wild type protein acts as a scaffold to coordinate complexes of other proteins
- Also acts as a transcriptional regulator